Por: MarketWatch Business February 09, 2023
International sales of Humira fell 26.5% from last year as the company lost patent protection in Europe and . However, revenue for the drug that treats Crohn’s disease grew 4.6% globally in the quarter to $5.58 billion, which was slightly above analysts’ estimates. said Thursday on a conference call that Humira sales were expected to fall 37% in the U.S. in 2023. That projection may be striking, but the company previously had expected... + full article
The New York Times USA Business January 28, 2023
In 2016, a blockbuster drug called Humira was poised to become a lot less valuable.The key patent on the best-selling anti-inflammatory medication, used to treat conditions like arthritis, was expiring at the end of the year. Regulators had blessed a rival version of the drug,... + más
Will More Women Patent Attorneys Lead To More Women Inventors? | Forbes
Samsung Beats IBM, Apple, Intel, Google For 2022 Patent Crown; 56% Of U.S. Patents Go To Foreign Firms | Forbes
MarketWatch USA Business January 22, 2023
A few weeks later, in December, the biotechnology company BeiGene stole the show at the American Society of Hematology’s big annual meeting in New Orleans. BeiGene showing its Btk inhibitor pill, Brukinsa, beating Imbruvica on efficacy and safety in a trial of CLL patients. ... + más
Shaikin: Baseball embracing the 'flukes' and plenty of added revenue this postseason | Los Angeles Times
Watch the wreck of the Brookhill ferry return to the waters of the Mississippi River | The Advocate
Fox Business USA Business December 31, 2022
Janus Henderson Investors director of research Matt Person explains why the U.S. dividend story has been so strong on 'The Claman Countdown.' S&P 500 companies spent a record amount on dividends this year, a trend that is expected to continue in 2023 despite a slowing... + más
How To Calculate Dividend Yield | Forbes
Dividends And Taxes: What You Need To Know | Forbes
MarketWatch USA Business December 27, 2022
The worst may be over for the stock market for this cycle, but many economists see more pain ahead for 2023, including a possible recession that will create poor financial-performance comparisons for companies and send stock prices even lower. Greg Adams, director of... + más
What Are the Duties of A Trustee? | Forbes
The 'Friday the 13th' series includes 12 horror movies — here's where to watch them all this Halloween season | Business Insider
MarketWatch USA Politics December 27, 2022
Forbes USA Tech December 05, 2022
Cigna’s pharmacy benefit manager Express Scripts will put “multiple biosimilar versions of Abbvie’s ... [+] expensive rheumatoid arthritis drug Humira in the “same position as the brand” on the PBM’s as a formulary in 2023. AbbVie's signature drug Humira is... + más
Cigna received millions of Medicare dollars based on invalid diagnoses, lawsuit claims | ABC News
How To Get Away With Corporate Murder: Unbundling And Disrupting Pharmacy Benefit Managers (Part 2) | Forbes
RTTNews USA Health October 28, 2022
AbbVie () announced Friday that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous bispecific antibody, for the treatment of adult patients with relapsed/refractory... + más
Don’t Pay for Cord-Blood Banking | The Atlantic
Prime Video’s Aparna Purohit Reveals How Madhuri Dixit Got Onboard For ‘Maja Ma’ | Forbes
About iurex | Privacy Policy | Disclaimer |